Patients ages 10 years and older with thalassemia and low risk myelodysplastic syndrome who receive regular red cell transfusions and have associated iron overload are eligible to participate.
The study involves administration of an experimental oral chelator daily for 24 weeks as well as medical record review, subject questionnaires, physical exam, ECG, chest x-ray (if clinically indicated), hearing and eye exams, and blood and urine tests to monitor for safety.